XSHG
600789
Market cap1.24bUSD
Dec 05, Last price
9.76CNY
1D
-0.61%
1Q
-1.91%
Jan 2017
30.66%
Name
Shandong Lukang Pharmaceutical Co Ltd
Chart & Performance
P/E
22.23
P/S
1.41
EPS
0.44
Div Yield, %
0.92%
Shrs. gr., 5y
0.37%
Rev. gr., 5y
10.80%
Revenues
6.23b
+2.30%
Net income
395m
+60.30%
CFO
403m
-33.31%
Dividend
Jun 21, 20240.09 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Lukang Pharmaceutical Co.,Ltd. manufactures and sells bio-pharmaceuticals and antibiotics in China. The company offers human and animal active pharmaceutical ingredients; human and animal preparations; bio-pesticides; herbal medicines; and amino acid. It is also involved in the sewage treatment, odor control, sewage facilities management, environmental protection material production and sale, and management of water disposal. The company exports its products to approximately 40 countries in Asia, Europe, Africa, and the United States. The company was formerly known as Jining Antibiotic Factory and changed its name to Shandong Lukang Pharmaceutical Co.,Ltd. in October 1993. Shandong Lukang Pharmaceutical Co.,Ltd. was founded in 1966 and is based in Jining, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||